The Analyst Landscape: 7 Takes On Avidity Biosciences
The Analyst Landscape: 7 Takes On Avidity Biosciences
分析师视角：对avidity biosciences的七种看法
In the preceding three months, 7 analysts have released ratings for Avidity Biosciences (NASDAQ:RNA), presenting a wide array of perspectives from bullish to bearish.
在过去的三个月中，有7位分析师发布了对Avidity Biosciences (纳斯达克：RNA) 的评级，呈现出从看好到看淡的各种观点。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他们最近评级的精简视图，显示了过去30天的不同情绪，并将其与前几个月进行比较。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $47.14, a high estimate of $60.00, and a low estimate of $35.00. Witnessing a positive shift, the current average has risen by 20.87% from the previous average price target of $39.00.
通过他们对12个月目标价格的评估，分析师提供了更深入的见解，揭示了平均目标价为$47.14，最高估价为$60.00，最低估价为$35.00。目前平均值已经比上一个平均目标价格高20.87%。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析师评级：详细剖析
In examining...
通过...
登录免费看全文
登录/注册